New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company’s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from _________ to _____________ Commission file number: 001-11460 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Ernexa Therapeutics Inc. (Exact name of registrant as specified in its charter) 1035 Cambridge St ...

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28. The study showed how engineered cells derived from stem cells could transform the treatment of ovarian cancer. The data revealed that these engineered cells, which release powerful immune-boosting ...

Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancerCAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purc ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's unwavering commitment to patient impact,"Breaking Through Defenses, Delivering Hope" CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company's new name: Ernexa TherapeuticsSM (NA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 1-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-1103425 (State or O ...

Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programsCAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting of its newly formed Scientific Advisory Board. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory board. "We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system's response to recognize and attack ovarian cancer cells. This successful proof-of-concept study ...

Company Announcement - Eterna Therapeutics appoints Dr Elena Ratner to its Board of Directors to lead strategic efforts in ovarian cancer research and treatment [1][2] - Dr Ratner brings extensive expertise in obstetrics gynecology and reproductive sciences from Yale University [1][4] - Eterna aims to accelerate advancements in innovative therapies for ovarian and breast cancers leveraging Dr Ratner's leadership and recent collaboration with MD Anderson Cancer Center [2] Product Development - Eterna's lead product ERNA-101 is an allogeneic pro-inflammatory cytokine (IL-7/IL-15)-secreting iMSC therapy targeting platinum-resistant ovarian cancer [5] - ERNA-101 enhances immune system response against tumors by improving immune cell infiltration and activation [3] - The company is also investigating ERNA-102 anti-inflammatory cytokine (IL-10)-secreting iMSCs for inflammatory/auto-immune disorders like rheumatoid arthritis [5] Strategic Direction - Eterna is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and expand developmental opportunities [5] - The company's focus on women's health is reinforced by its collaboration with MD Anderson Cancer Center and Dr Ratner's expertise [2][4] - Eterna's scientific data shows promise in addressing the challenges of ovarian cancer treatment including resistance and high recurrence rates [3]